

218
218

The New England Journal of Medicine

Copyright, 1970, by the Massachusetts Medical Society

Volume 283

AUGUST 20, 1970

Number 8

CLOTTING CHANGES, INCLUDING DISSEMINATED INTRAVASCULAR COAGULATION, DURING RAPID RENAL-HOMOGRAFT REJECTION*

THOMAS E. SEARZL, PH.D., M.D., HANS J. BOEHMIG, M.D., HIROSHI AMEMIYA, M.D.,
CURTIS B. WILSON, M.D., FRANK J. DIXON, M.D., GEOFFREY R. GILES, M.D.,
KENNETH M. SIMPSON, M.D., AND CHARLES G. HALGRIMSON, M.D.

Abstract One of two patients in whom early homograft rejection developed after renal transplantation had many antidonor antibodies before operation. By the measurement of gradients across intracorporeal and extracorporeal homografts in this patient, the new kidneys were shown to sequester host immunoglobulins, platelets, white cells and clotting factors. Moreover, the renal venous blood then contained fibrinolytic activity. This presensitized recipient, as well as a second patient who did not have detectable preformed humoral antibodies,

gave evidence from clinical observation and from the various clotting tests of disseminated intravascular coagulation with fibrinolysis and a severe bleeding diathesis. Immunofluorescent and histologic studies revealed a laying down of fibrin in the homograft vessels that continued in some cases to cortical necrosis of the transplanted kidneys or, alternatively, receded at the time fibrinolysis occurred. The variety of rejection seen in these patients has been characterized as an immunologically induced coagulopathy.

WHEN a kidney homograft is revascularized in a recipient who is presensitized to donor antigens there is a substantial risk of either accelerated or hyperacute rejection of the transplant.^{1,2} The mechanism of the immediate destruction has been disputed. Two years ago in this journal, a clinical report from our institutions³ suggested that an instantaneous antigen-antibody reaction or other mechanisms could precipitate a coagulopathy like that of the Schwartzman reaction and that the consequent fibrin thrombi could occlude the renal microvasculature and be responsible for cortical necrosis. The principal evidence in support of this contention was from special histologic examinations. Unfortunately, clotting assays were not obtained in these patients.

A subsequent publication by Colman and Merrill and their associates⁴ confirmed that there were massive fibrin deposits in two human kidneys that had been hyperacutely rejected by apparently presensitized recipients.⁵ However, no systemic clotting

changes could be detected in either of their patients, nor was there an arteriovenous gradient of any of the measured coagulation factors across the kidney in the most completely studied of these cases. Because of the negative findings, there was no satisfactory explanation even for the local intravascular coagulation that the authors postulated and no evidence whatever that there had been a systemic clotting disorder at any time.

In contrast, studies from our laboratories have shown that noteworthy alterations in local or systemic coagulation regularly occur in presensitized dogs after the transplantation of the kidney, liver or spleen.⁷ The same thing has been seen in two recently treated patients whose renal homografts failed promptly. In both these human recipients, studies obtained revealed consumption of clotting factors either within the kidney or systemically, as well as fibrinolysis and a bleeding diathesis.

METHODS

The techniques of renal transplantation and postoperative care were standard.⁸ Immunosuppression was with azathioprine, prednisone and intramuscular horse antilymphocyte globulin (ALG).⁹

Immunologic Studies

Tissue typing of the donors and recipients was carried out both in Denver and by Dr. Paul Terasaki in Los Angeles with the use of a serologic method.¹⁰ In addition, preformed leukoaggluti-

*From the Department of Surgery, University of Colorado School of Medicine and Denver Veterans Administration Hospital, Denver, Col., the Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, Cal. (address reprint requests to Dr. Starzl at the Veterans Administration Hospital, 1055 Clermont St., Denver, Col. 80220).

This is publication No. 400 from the Scripps Clinic and Research Foundation.

Supported by United States Public Health Service grants (AI-04152, AI-07007, AI-AM-08898, AM-12148, AM-06344, AM-07772, FR-00051, and FR-00069) from the U.S. Public Health Service and by a U.S. Public Health Service contract (43-68-621).

Abbreviations Used

ALG:	antilymphocyte globulin
DEAE:	diethylaminoethanol
FSP:	fibrin split products
PTAH:	phosphotungstic acid hematoxylin

nins,¹¹ lymphocytotoxins¹² and heterohemagglutinins against sheep red blood cells¹³ were looked for in the serums of the recipients. With a mixed agglutination test,¹⁴ Professor Felix Milgrom, of Buffalo, New York, examined these serums against HeLa and HEp-2 cell lines.

When preformed antibodies were found in Patient 1, the serum was fractionated with diethylaminoethanol (DEAE) cellulose column chromatography with the use of gradient elution.¹⁵ The fractions were identified for immunoglobulin class by immunoelectrophoresis.¹⁶ In the fractions, the presence or absence of leukoagglutinins, lymphocytotoxins and heterohemagglutinins was determined. Quantitative determination of IgG was performed with a commercial immunoplate.^{*17}

Hematologic and Coagulation Studies

Hematocrit, white-cell counts and platelet counts¹⁸ were assayed in blood anticoagulated with ethylene diamine tetra-acetic acid (EDTA).

Platelet-poor plasma was obtained by mixture of 9 parts of blood with 1 part of anticoagulant (3 parts 0.1 M sodium citrate, 2 parts 0.1 M citric acid) and centrifugation for 20 minutes at 4°C and 4000 rpm. The following tests were done in fresh plasma: euglobulin lysis time¹⁹; thrombin time with 5 U per milliliter of thrombin²⁰; prothrombin time with activated rabbit brain thromboplastin; and partial thromboplastin time.²¹ Fibrinogen,²² prothrombin (Factor II),²³ accelerator globulin (Factor V),²⁴ antihemophilic globulin (Factor VIII)²⁵ and plasma thromboplastin component (Factor IX)²⁶ were assayed in frozen plasma after storage at -80°C.

For the estimation of fibrin split products (FSP) 2-ml samples of blood were collected in glass tubes containing 20 U of kallikrein trypsin inhibitor (Trasylol). When clotting had occurred, 50 U of thrombin (Parke-Davis) were added to each tube. After incubation at 37°C for two hours, serum was obtained by centrifugation at 2000 rpm for 10 minutes. The FSP in this serum were assayed by the method of Claman and Merrill²⁷ except that rabbit antihuman fibrinogen antiserum (Hyland) was employed. FSP were also estimated by the semiquantitative method of Stiehm and Trygstad.²⁸

Immunofluorescent and Histologic Studies

Tissue samples were snap frozen on dry ice for immunofluorescent study or fixed in 10 per cent formalin for histologic study with hematoxylin eos-

sin, periodic acid-Schiff (PAS) and phosphotungstic acid-hematoxylin (PTAH) stains. Immunofluorescent staining was done with antisera specific for human IgG, IgA, IgM, C3, fibrinogen and equine gamma globulin. The specificity of the antiserum was shown by immunoelectrophoresis and double diffusion in 1 per cent agarose. Immunofluorescent control studies included sections of normal kidney, spleen and liver blocking with unconjugated reagents and absorption of the reagents with their specific antigens.

CASE REPORTS

CASE 1. From January to November, 1969, a 45-year-old multiparous woman on chronic hemodialysis was given an estimated 125 transfusions of A+ blood. Renal homotransplantation was performed on November 28, 1969, from a cadaveric donor of O+ blood type. The recipient serum contained a variety of antidonor antibodies, including lymphocytotoxins, leukoagglutinins and heterohemagglutinins, as well as cytotoxins against the lymphocytes of 99 per cent of random unrelated people. In addition, the preoperative serum was found by Professor Milgrom to have a positive test by the mixed agglutination technic. There were incompatibilities in the antigenic groups HL-A8 and Fe6.

Because the rejection of a kidney by a presensitized canine recipient can be ameliorated with a prior graft from the same donor,⁷ it was planned to transplant temporarily a kidney and if necessary a spleen or liver before the definitive renal homograft was placed. Consequently, the donor left kidney, which had a small polar infarct, was removed first and revascularized in the usual way in the recipient right extraperitoneal space. The anticipated immediate rejection did not occur, and the homograft excreted small quantities of bloody urine. Because of the polar infarct, the organ was removed after 80 minutes and replaced with the donor's right kidney. With the 2d kidney diuresis promptly occurred. However, a generalized ooze in the operative wound was now noted. There was evidence of disseminated intravascular coagulation (discussed below), and for that reason a brief course of heparin therapy was tried. Re-exploration for the control of bleeding was necessary 18 hours after transplantation and again after two days. Both times the cortex of the homograft was pink. The transplant became anuric in 5 days, and it was removed after 13 days. The renal artery and vein were open, but the kidney had undergone nearly complete cortical necrosis.

On January 22, 1970, a 7-year-old cadaveric donor of O+ blood type and with histocompatibility mismatches of HL-A groups 2, 3 and 7 became available. One of the kidneys was interposed in the arteriovenous shunt used for hemodialysis. It became pink and made urine for 40 minutes. Its surface then turned mottled and cyanotic as it underwent hyperacute rejection. There was no clinical evidence of abnormal bleeding at this time or subsequently.

CASE 2. A 27-year-old man with end-stage glomerulonephritis was given an estimated 50 blood transfusions in the 6 months before admission to the Denver Veterans Administration Hospital. During this time, he had 3 abdominal operations for duodenal ulcer or intestinal obstruction. Renal homotransplantation was performed from his 24-year-old sister. Both donor and recipient were O+ blood type. The only antigenic mismatch recognized by Dr. Paul Terasaki was of group Fe4. No preformed recipient antibodies of the kinds described in Case 1 were detected. At the time of renal transplantation on November 10, 1969, the patient's kidneys, which had been excreting 400 to 600 ml of urine per day, were not disturbed. The homograft began a diuresis that continued briskly for six hours and then dropped off,

*Hyland Laboratories, Los Angeles, Cal.

so that by 12 hours the urine volume was about the same as it had been before operation (20 to 25 ml per hour). By 36 hours there was total anuria, and the patient had become comatose.

As urine flow diminished there were multiple clinical signs of a serious bleeding diathesis, including hematuria, epistaxis, subconjunctival hemorrhages, the appearance of blood in the upper gastrointestinal aspirate and hemorrhage from all the skin wounds. Multiple blood cultures were negative. Extensive liver-function tests gave normal results for another day before exhibiting deterioration. After 36 hours, heparin was given intravenously during a 10-hour hemodialysis on a Kol artificial kidney. The patient was then returned to the operating room, where all the residual stomach was removed as well as the enlarged spleen. The liver was soft and mottled and was thought to have multiple small necrotic areas. The resected gastric remnant had extensive coagulative mucosal necrosis. Bleeding continued from multiple sites for the remaining 1½ days of life. During this time the right arm and left leg became pulseless. Moreover, several islands of anterior thoracic and abdominal skin became gangrenous. The patient died almost 4 days after revascularization of the renal homograft.

At autopsy, the transplanted kidney was soft and contained multiple petechial hemorrhages; the renal artery and vein were patent. There was hemorrhage into the lungs, peritoneal cavity and intestines. The esophageal, intestinal and colonic mucosae were friable, with multiple necrotic areas. The liver was studded with multiple yellow infarcts measuring 1 to 30 mm in diameter. The main hepatic artery and

its branches were free of thrombosis. Unfortunately, the femoral artery that supplied the lifeless left leg was not dissected. The right brachial artery was filled with a fresh occlusive thrombus.

RESULTS

Immunologic Studies

In the preoperative serum of Case 1, the preponderance of the leukoagglutinins, lymphocytotoxins and heteroagglutinins were localized in IgG. The antibodies were all absorbed in vitro by the stored hepatic cells of the cadaveric renal donor.

Within a few minutes after revascularization of the first kidney, the antibody titers in samples from the homograft renal vein became less than in systemic blood (Fig. 1). Moreover, the levels of systemic leukoagglutinins and lymphocytotoxins fell perceptibly (Fig. 1). After the first graft was removed and replaced by the contralateral kidney from the same donor, systemic lymphocytotoxins drifted even lower (Fig. 1). Arteriovenous gradients of IgG and IgA developed after the transplantation of both organs (Fig. 1), but this was inexplicably accompanied by sudden increases in the systemic serum concentration of the IgG. When the third




Figure 1. Antibodies and Immunoglobulin Concentrations in Systemic Blood (Solid Lines) and in Samples from the Renal Veins Draining the Homografts (Dashed Lines) in Case 1. The first two kidneys were consecutively transplanted in the right iliac fossa after removal from the same cadaveric donor. The final kidney was revascularized extracorporeally.

homograft was revascularized on the arm shunt, almost two months later, the observations were essentially the same except that antidonor leukoagglutinins were not present in advance of revascularization (Fig. 1).

In Case 2 humoral antibodies were never detectable.

Hematologic and Coagulation Studies

In Case 1 the first renal homograft sequestered leukocytes, platelets, fibrinogen (Factor I) and the Factors II, V and VIII, especially in the first 10 minutes after revascularization (Fig. 2). Since the organ had been cooled by perfusion with 200 ml of cold electrolyte solution that contained 10 mg of heparin, residual heparin that appeared in the renal venous blood contributed to the decrease in Factor V activity.²⁰ However, the other measurements, including Factors I, II and VIII, were not greatly influenced by the heparin.




Figure 2. Intraoperative Coagulation Studies in Systemic Blood (Solid Lines) and in Venous Blood Returning from the Homograft (Dashed Lines) in Case 1 (First Homograft). Note the consumption of platelets and clotting factors and the evidence of fibrinolytic activity in the venous effluent (see text). FSP are measured quantitatively.

At the same time as the foregoing intrarenal consumption or shortly afterward, there was prolongation of thrombin, prothrombin and partial thromboplastin times in the blood leaving the homograft (Fig. 2). Although some of these changes were undoubtedly due to residual heparin, much of the antithrombin activity was thermolabile and therefore due to FSP.²⁰ For example, the thrombin time of a 1:1 mixture of the 20-minute plasma with normal

plasma was shortened from 110 seconds to 28 seconds if the test plasma was first heated at 60°C for 20 minutes. The FSP also were directly measured by the immunoassay method and revealed striking fibrinolysis (Fig. 2).

During the 80 minutes when the first kidney was vascularized, changes occurred in the systemic blood which were similar to but much less marked (Fig. 3) than those just described in the homograft venous effluent. Subsequently, starting at about the time when the first organ was removed and continuing after the second kidney was transplanted, the abnormalities became profound, with a marked drop of platelets and all clotting factors (Fig. 3). In addition, the euglobulin lysis time became shortened to less than 10 minutes, and large quantities of FSP




Figure 3. Profound and Lasting Systemic Coagulation Changes in Case 1 Produced by the Consecutive Transplantation of Two Kidneys (I and II) from the Same Donor. Note that the data are an extension of the more detailed studies presented in Figure 2 and that the time between transplantation of the first and second kidneys is 80 minutes. EACA indicates epsilon aminocaproic acid. The two operations were for control of wound hemorrhage.

were detectable (Fig. 3). These findings of a generalized consumptive coagulopathy with fibrinolysis corresponded to the development of a grave bleeding diathesis. About 10 hours after transplantation, systemic heparin (1.3 mg per kilogram of body weight) and epsilon aminocaproic acid (0.1 g per kilogram) were administered. During the next several

days the evidence of intravascular clotting and fibrinolysis receded approximately at the same time or shortly before the homograft ceased to function.

The third homograft, which was revascularized on the dialysis shunt eight weeks later, was not flushed with a heparin-containing solution. There was an immediate entrapment of formed blood elements and of all clotting factors within the transplant (Fig. 4). Traces of FSP were detected in the renal venous blood. No notable changes of thrombin, prothrombin and partial thromboplastin times were observed. Except for a transient decrease in the number of arterial platelets, there were no systemic changes.




Figure 4. Extracorporeal Transplantation of a Child Donor's Kidney in Case 1.

Hematologic and coagulation changes occurred in renal arterial (solid lines) and renal venous (dashed lines) blood. Note the local consumption but no detectable systemic effect.

The coagulation studies in Case 2 were far less complete and are summarized in Figure 5. Within five to 10 hours after revascularization of the homograft the platelets and fibrinogen were reduced to 10 and 15 per cent respectively of their preoperative levels. With the tube precipitin method of Stiehm and Trygstad²⁸ fibrin degradation products accounted for 15 per cent of the column length (normal, less than 0.4 per cent). The prothrombin and partial thromboplastin times were prolonged to 35 and 69 seconds (Fig. 5). The various abnormalities were temporarily improved on the second postoperative day when heparin was given (Fig. 5).

Complete hematologic and clotting studies of systemic blood were obtained in six consecutive patients who recovered without incident after renal

transplantation. Appreciable changes were not detected.

Immunofluorescent and Histologic Studies

Since these results were in accord with published observations,^{2,3,5,7,31} attention will be confined to special features. In Case 1, the first of the three homografts was biopsied at 20, 40 and 80 minutes. The glomerular capillaries of all three specimens




Figure 5. Urinary Output, Immunosuppressive Treatment and Coagulation Studies in a 27-Year-Old Recipient Whose Renal Homograft Underwent a Violent Early Rejection.

A disseminated intravascular coagulation, fibrinolysis and a bleeding diathesis developed. FSP were measured with a semiquantitative analysis.²⁸

contained irregular fibrin deposits. Equivocal deposits of C3 were in patchy distribution along the glomerular basement membrane at 40 minutes, but stainable immunoglobulins were otherwise not identified. The number of polymorphonuclear leukocytes per glomerulus was 30 to 40 at 40 minutes but was reduced by 80 minutes. The second homograft after 13 days had the cortical necrosis, fibrin plugging of vessels and nonspecific immunoglobulin deposition described in an earlier paper.³ The third kidney, which was sampled at 2 1/4, 24, 61, 129 and 146 minutes, had findings similar to those in the first graft except that the C3 was greater and there were patchy traces of IgG and IgM that became less distinct in the later specimens.

The immunofluorescent staining in Case 2 re-

vealed fibrin to be present in the peritubular areas of the homograft and to a lesser extent in the native kidneys which had been affected by immune-complex glomerulonephritis. No fibrin was present in the *glomeruli* of either the native or the transplanted kidneys. A widespread focal deposition of fibrin was present in samples from the splenectomy, and large amounts of fibrin were present in the liver surrounding the necrotic cells of a severe midlobular necrosis. The hepatic fibrin also stained with the PTAH stain in fibrillar pattern. No specific deposits of IgG, IgA, IgM, C3 or equine gamma globulin were seen in the renal homograft or the native spleen or liver.

DISCUSSION

The emphasis that has been placed in this report on coagulation changes has not been intended to minimize the etiologic role of immunologic factors in abrupt renal rejection. It has been accepted that hyperacute renal rejection is the reflection of sensitization to antigens found in the donor^{1,5,7,32} although it has also been pointed out⁵ that antidonor antibodies apparently can be present despite good histocompatibility match and that none of the current serologic methods can predict the sensitized state with total reliability. One of the recipients of the present study had preformed antibodies detectable by four different procedures, whereas the same examinations were negative in the other patient. Yet similar changes in coagulation consequent to homograft transplantation swiftly evolved in the systemic blood of both the recipients. Such changes were not seen in six other patients who had benign convalescence after renal transplantation.

The observations in the two patients of the present report were analogous to those reported by Simpson et al.,⁷ who sensitized dogs by repeated skin grafts and subsequently transplanted the liver, spleen or kidney from the same donor. The canine organs promptly sequestered antigraft humoral antibodies, platelets, white cells and clotting factors. Moreover, the graft venous effluent contained fibrinolytic activity. In about a fourth of the dogs a systemic coagulation disorder then developed, with abnormalities often associated with disseminated intravascular coagulation.³³⁻³⁵

Similar trapping of antibodies, formed blood elements and clotting factors was documented in Case 1 after the transplantation of consecutive grafts from the same donor. Nevertheless, these kidneys were not destroyed immediately, possibly because the fibrinolysis that quickly developed had a protective effect. The findings in sequential renal-graft biopsies were consistent with this interpretation, with an initial laying down and later removal of fibrin in the vascular system. At the same time, there was first entrapment and then release by the homograft of both platelets and white cells. Conceivably, fac-

tors that contributed to the life-threatening systemic coagulopathy originated from the transplant as well. In the other less completely studied patient (Case 2), eventually lethal changes occurred within five hours that were diagnostic of disseminated intravascular coagulation with consumption of clotting factors, fibrinolysis and a clinical bleeding diathesis.

Further comment is appropriate about the variability with which alterations in coagulation may become manifest in a given recipient. In Case 1, whose first two renal homografts provoked a life-threatening bleeding diathesis, a child cadaveric kidney was later inserted into the arteriovenous shunt used for dialysis. There was immediate consumption of antibodies, white cells, platelets and clotting factors within the graft, which became cyanotic in less than an hour. Hyperacute rejection apparently occurred so rapidly on this occasion that secondary events such as systemic fibrinolysis or other generalized clotting alterations did not have time to develop before the transplanted kidney was functionally excluded from the circulation by its devascularization. Thus, the outcome in terms of both graft survival and host peril presumably depends on many factors discussed at length previously,⁵ including the kind and intensity of the initiating immunologic reaction, as well as the balance of coagulation and fibrinolysis with which the host responds. The observations of Braun and Merrill³¹ and Busch et al.³⁶ are consistent with this interpretation.

In principle, the chain of events in this kind of homograft rejection is not obviously different from that seen after the heterotransplantation of organs between animals of genetically diverse species.³⁷ With the hyperacute rejection of both homografts and heterografts, the means of inducing a local or generalized coagulopathy have not been identified although likely mechanisms are not difficult to envision. Since the preformed antibodies appear to react with antigens in the transplants, clotting could be induced directly by the antibody-antigen reaction³⁸⁻⁴⁰ or by the consequent tissue injury. In addition, antibody-antigen reactions attract polymorphonuclear leukocytes via C' activation,⁴¹ and these white cells appear capable of inducing clotting⁴² and are an important if not essential intermediary in the causation of the thrombosis seen in the local⁴³ and generalized⁴² Shwartzman reactions. Heavy accumulations of polymorphonuclear leukocytes and thrombosis have been seen in man, in whom preformed antibodies induced immediate hyperacute rejections of renal transplants.⁴⁵⁻⁴⁷ In Case 1 of the present report, white cells were promptly sequestered by the homograft as shown by noteworthy arteriovenous gradients. The polymorphonuclear leukocytes were obvious in the sequential biopsies within 40 minutes and then apparently began to leave the grafts.

In a past publication⁵ the possibility was dis-

enced that a coagulopathy (and consequent hyperacute rejection) could be precipitated by an antigen-antibody reaction outside, as well as within, a renal graft. If the immunologic reaction occurred at a distance from the homograft, the transplanted kidney could conceivably be destroyed as an "innocent bystander" by becoming the passive repository of fibrin products that are formed elsewhere and filtered out by the renal microcirculation. From the animal experiments carried out by Simpson et al.⁷ and from the further observation in the human patients herein reported, it seems clear that the antigen-antibody reaction that triggers the coagulopathy probably is nearly always within the transplanted organ, that the coagulation changes often are confined to the transplant, and that if systemic coagulation abnormalities develop, these are derivative from events within the homograft. Under these circumstances, a systemic coagulation disorder initiated in the kidney and then secondarily occurring elsewhere could be conceived as having a boomerang effect in which the fibrin strands from distant intravascular coagulation could be circulated back to a homograft and contribute to its further injury.

Various descriptive terms have been applied to hyperacute rejection, and its different aspects have been emphasized by comparison to the Arthus reaction,⁴ inverse anaphylaxis³ and the generalized Shwartzman reaction.⁵ Each of these classic immunologic phenomena is, or can be, initiated by interaction of antibody and antigen. After the immunologic reaction in each of these, there are multiple secondary events, including inflammation and coagulation. The importance of the coagulation varies in the different phenomena, being the central event in the generalized Shwartzman reaction. However, since all these classic terms have additional connotations that may not apply directly to hyperacute rejection, it is probably preferable simply to define this kind of rejection as an "immunologically mediated coagulopathy that may lead to the devascularization and destruction of a transplanted organ and that sometimes results in systemic coagulation abnormalities."

REFERENCES

1. Terasaki PI, Marchione H, Starzl TE: Serotyping of human lymphocyte antigens: preliminary trials on long term kidney homograft survivors. *Histocompatibility Testing, 1965*, Edited by PS Russell, HJ Winn, DB Amos, Washington, DC, National Academy of Sciences-National Research Council, 1965 (Publication No 1229), pp 83-95.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al: Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. *Lancet* 2:662-665, 1966.
3. Williams GM, Hume DM, Hudson RP, Jr, et al: "Hyperacute" renal-homograft rejection in man. *New Eng J Med* 279:611-618, 1968.
4. Terasaki PI, Thrasher DL, Hauber FH: Serotyping for homograft transplantation. XIII. Immediate kidney transplant rejection and associated preformed antibodies. *Advance in Transplantation*, Edited by J Dausset, J Hamburger, G Mathe, Copenhagen, Einar Munksgaard, 1968, pp 225-229.
5. Starzl TE, Lerner RA, Dixon FJ, et al: Shwartzman reaction after human renal homograft transplantation. *New Eng J Med* 278:642-648, 1968.
6. Colman RW, Braun WF, Busch GJ, et al: Coagulation studies in the hyperacute and other forms of renal-allograft rejection. *New Eng J Med* 281:685-691, 1969.
7. Simpson KM, Bunch DL, Amemya H, et al: Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. *Surgery* 68:77-85, 1970.
8. Starzl TE: *Experience in Renal Transplantation*. Philadelphia, WB Saunders Company, 1964.
9. *Idem*: *Experience in Hepatic Transplantation*. Philadelphia, WB Saunders Company, 1969.
10. Terasaki PI, Singal DP: Human histocompatibility antigens of leukocytes. *Ann Rev Med* 20:175-188, 1969.
11. van Rood JJ, van Leeuwen A: Leukocyte grouping: a method and its application. *J Clin Invest* 42:1382-1390, 1963.
12. Terasaki PI, McClelland JD: Microdroplet assay of human serum cytotoxins. *Nature (London)* 204:998-1000, 1964.
13. Kashiwagi N, Sherer D, Townsend CM, et al: Antibody localization in horse, rabbit, and goat A.I.S. *Surgery* 67:789-798, 1970.
14. Milgrom F, Litvak BI, Kano K, et al: Humoral antibodies in renal homograft. *JAMA* 198:226-230, 1966.
15. Fahey JL, Terry FW: Ion exchange chromatography and gel filtration. *Handbook of Experimental Immunology*, Edited by DM Weir. Philadelphia, FA Davis Company, 1967, pp 19-43.
16. Scheidegger JJ: Une micro-methode de l'immuno-électrophorèse. *Int Arch Allerg* 7:103-110, 1955.
17. Darcy DA: A quantitative application of the agar-diffusion plate: the estimation of specific proteins in serum. *Immunology* 3:325-335, 1960.
18. Brecher G, Cronkite EP: Morphology and enumeration of human blood platelets. *J Appl Physiol* 3:365-377, 1950.
19. Buckell MI: The effect of citrate on globulin methods of estimating fibrinolytic activity. *J Clin Path* 11:403-405, 1958.
20. von Kaulla KN, von Kaulla E: Estimation of the thrombin time of plasma. *Blood Coagulation, Hemorrhage, and Thrombosis: Methods of study*. Second edition. Edited by IM Tocantins, LA Kazal. New York, Grune and Stratton, 1964, pp 335-340.
21. Proctor RR, Rapaport SI: The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. *Amer J Clin Path* 36:212-219, 1961.
22. Ratnoff OD, Menzie C: A new method for the determination of fibrinogen in small samples of plasma. *J Lab Clin Med* 37:316-320, 1951.
23. Owren PA, Aas K: The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. *Scand J Clin Lab Invest* 3:201-208, 1951.
24. Deutsch E, Schaden W: Zur Reinigung und Charakterisierung des VII. Blutgerinnungsfaktors. *Biochem Z* 324:266-279, 1953.
25. Pool JG: Preparation and testing of antihemophilic globulin (Factor VIII) sources for transfusion therapy in hemophilia: description of a new sterile concentrate process for blood banks. *Scand J Clin Lab Invest Suppl* 84:70-77, 1965.
26. Henderson ES, Rapaport SI: The thrombotic activity of activation product. *J Clin Invest* 41:235-244, 1962.
27. Claman HN, Merrill D: Quantitative measurement of human gamma-2, beta-2A, and beta-2M serum immunoglobulins. *J Lab Clin Med* 64:685-693, 1964.
28. Stehm ER, Trygstad CW: Split products of fibrin in human renal disease. *Amer J Med* 46:774-786, 1969.
29. Soulier JP: Action of heparin in the blood coagulation system. *Thromb Diath Haemorrh Suppl* 11:37-44, 1963.
30. Kowalski E: Fibrinogen derived inhibitors of blood coagulation. *Thromb Diath Haemorrh Suppl* 1:211-223, 1960.
31. Braun WF, Merrill JP: Urine fibrinogen fragments in human renal allografts: possible mechanism of renal injury. *New Eng J Med* 278:1366-1371, 1968.
32. Lemmet M, Pinn VW, Flax MH, et al: Humoral antibodies in renal allotransplantation in man. *New Eng J Med* 282:111-117, 1970.
33. McKay DG: *Disseminated Intravascular Coagulation: An intermediary mechanism of disease*. New York, Hoeber Medical Division, Harper and Row, 1964.
34. McKay DG, Shapiro SS: Alterations in the blood coagulation system induced by bacterial endotoxin. I. In vivo (generalized Shwartzman reaction). *J Exp Med* 107:353-367, 1958.

35. McKay DG: Progress in disseminated intravascular coagulation. *Calif Med* 111:186-198, 1969
36. Busch GJ, Braun WF, Carpenter CB, et al: Intravascular coagulation (IVC) in human renal allograft rejection. *Transplantation Proc* 1:267-270, 1969
37. Rosenberg JC, Broersma RJ, Bullemer G, et al: Relationship of platelets, blood coagulation, and fibrinolysis to hyperacute rejection of renal xenografts. *Transplantation* 8:152-161, 1969
38. Bettex-Galland M, Lüscher FF, Simon G, et al: Induction of viscous metamorphosis in human blood platelets by means other than by thrombin. *Nature (London)* 200:1109-1110, 1963
39. Robbins J, Stetson C A Jr.: An effect of antigen-antibody interaction on blood coagulation. *J Exp Med* 109:1-8, 1959
40. Goeckel DJ, Osler AG: *In vitro* damage of rabbit platelets by an unrelated antigen-antibody reaction. I. General characteristics of the reaction. *J Immun* 94:236-246, 1965
41. Ward PA, Cochrane CG: Bound complement and immunologic injury of blood vessels. *J Exp Med* 121:215-234, 1965
42. Horn RG, Collins RD: Studies on the pathogenesis of the generalized Shwartzman reaction: the role of granulocytes. *Lab Invest* 18:101-107, 1968
43. Stetson CA, Good RA: Studies on the mechanism of the Shwartzman phenomenon: evidence for the participation of polymorphonuclear leucocytes in the phenomenon. *J Exp Med* 93:49-64, 1951
44. Williams GM, Lee HM, Weymouth RF, et al: Studies in hyperacute and chronic renal homograft rejection in man. *Surgery* 62:204-212, 1967

EVIDENCE FOR AN ETIOLOGIC ROLE OF ADENOVIRAL INFECTION IN PERTUSSIS SYNDROME*

JAMES D. CONNOR, M.D.

Abstract Eleven of 13 infants and children with the clinical diagnosis of pertussis syndrome were excreting adenovirus Type 1, 2, 3 or 5 from the respiratory, intestinal or genitourinary tract. Seven of these patients had serologic evidence of recent or current infection. In all patients cultures for *Bordetella*

pertussis or *parapertussis* were negative, and the majority had no evidence of pertussis infection, as determined by rises in antipertussis agglutinins. These findings add to the evidence of an etiologic association between adenoviral infection and the pertussis syndrome in cases occurring sporadically.

THE incidence of clinical whooping cough in this country has greatly declined since pertussis immunization has come into general use.¹ However, pertussis has not been eradicated; endemic cases and outbreaks² continue to occur in this and other developed countries.³ In part, this is due to the fact that satisfactory immunization fails to reach fairly large segments of the total population⁴ and that booster vaccine is not generally used in older groups.² Generally, in the United States, it is accepted that the great majority of cases of clinical whooping cough occurring in the inadequately immunized child are caused by infection with *Bordetella pertussis*, with a very occasional case due to *B. parapertussis*⁵ and, rarely, *B. bronchiseptica*.⁶

Recently, there have been several reports of a clinical illness closely resembling or identical with whooping cough without definitive evidence of *B. pertussis* infection. In one of these, adenoviruses were isolated from four patients, and antibody rises indicated recent adenovirus infection in the family of the index cases.⁷ In another, intranuclear inclusion bodies in lung tissue, along with the pathological findings of necrotizing bronchiolitis, suggested the presence of adenoviral infection.⁸ More recently, an additional case was reported in which adenovirus Type 5 infection was present in lung, liver and kidney; a sibling with a similar illness and other family members did not have serologic evidence of pertussis infection.⁹ This report presents additional

experience with adenoviral infection and the clinical pertussis syndrome occurring over a 30-month period in Miami, Florida.

MATERIALS AND METHODS

Study Group

A majority of the infants and children included herein first came to Jackson Memorial Hospital for primary care; the remainder were referred for investigation as sporadically occurring cases of pertussis syndrome between 1965 and 1968. A past history was obtained, and physical examination performed by at least two pediatricians, including the investigator. Multiple observations were made by these pediatricians and others throughout the course, and so far as possible, patients were followed for a period into convalescence. All patients were carefully examined and found to be free of other diseases. Serial x-ray examinations of the lungs were performed in most cases in which a first x-ray film was interpreted as abnormal.

Control Group

Infants and children hospitalized with other types of respiratory illness were used as controls, matched for age and socioeconomic group during the same period as the study group.

Microbiology

In a majority of cases, nasopharyngeal swabs were taken during induced coughing paroxysms and swabbed onto Bordet-Gengou plates, once or several times during the paroxysmal stage of illness. Cough plates were taken in some; both were held at 36.5°C for five to seven days. Bordet-Gengou

*From the Department of Pediatrics, University of Miami School of Medicine, Miami, Fla. (address reprint requests to Dr. Connor at the Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, Cal. 92037).

Supported in part by grants (AI 07719, CA 04036 and RR 00261) from the U.S. Department of Health, Education, and Welfare.